Search research articles
Contact Us
Filters
Showing results (11-20 of 20) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 20 results.
Leukemia Research
|
July 31, 2014
Predictive factors for a single successful cytapheresis session during the first mobilisation
A C Gac, J J Parienti, S Chantepie, et al.
European Journal of Nuclear Medicine
|
February 7, 2001
Clinical relevance of gallium-67 scintigraphy in lymphoma before and after therapy
C Delcambre, O Reman, M Henry-Amar, et al.
Transfusion Clinique Et Biologique : Journal De La Societe Francaise De Transfusion Sanguine
|
May 19, 2009
[Pulmonary complications of transfusion (TACO-TRALI)]
P Renaudier, D Rebibo, C Waller, et al.
Leukemia Research
|
August 2, 2011
Ferritin level at diagnosis is not correlated with poorer survival in non RBC transfusion dependent lower risk de novo MDS
S Park, R Sapena, C Kelaidi, et al.
British Journal of Haematology
|
May 10, 2006
High-dose darbepoetin alpha in the treatment of anaemia of lower risk myelodysplastic syndrome results of a phase II study
L Mannone, C Gardin, M C Quarre, et al.
Leukemia
|
February 2, 2013
Long-term outcome of anemic lower-risk myelodysplastic syndromes without 5q deletion refractory to or relapsing after erythropoiesis-stimulating agents
C Kelaidi, S Park, R Sapena, et al.
Leukemia
|
January 20, 2009
Is there a role for all-trans retinoic acid in combination with recombinant erythropoetin in myelodysplastic syndromes? A report on 59 cases
R Itzykson, S Ayari, D Vassilief, et al.
Leukemia Research
|
April 20, 2023
Effect of single-unit transfusion in patients treated for haematological disease including acute leukemia: A multicenter randomized controlled clinical trial
S P Chantepie, J B Mear, A R Briant, et al.
Annals of Hematology
|
January 30, 2013
High response rate and improved exercise capacity and quality of life with a new regimen of darbepoetin alfa with or without filgrastim in lower-risk myelodysplastic syndromes: a phase II study by the GFM
C Kelaidi, O Beyne-Rauzy, T Braun, et al.
Leukemia
|
October 27, 2015
Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion
A Toma, O Kosmider, S Chevret, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 20) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 20 results.
Leukemia Research
|
July 31, 2014
Predictive factors for a single successful cytapheresis session during the first mobilisation
A C Gac, J J Parienti, S Chantepie, et al.
European Journal of Nuclear Medicine
|
February 7, 2001
Clinical relevance of gallium-67 scintigraphy in lymphoma before and after therapy
C Delcambre, O Reman, M Henry-Amar, et al.
Transfusion Clinique Et Biologique : Journal De La Societe Francaise De Transfusion Sanguine
|
May 19, 2009
[Pulmonary complications of transfusion (TACO-TRALI)]
P Renaudier, D Rebibo, C Waller, et al.
Leukemia Research
|
August 2, 2011
Ferritin level at diagnosis is not correlated with poorer survival in non RBC transfusion dependent lower risk de novo MDS
S Park, R Sapena, C Kelaidi, et al.
British Journal of Haematology
|
May 10, 2006
High-dose darbepoetin alpha in the treatment of anaemia of lower risk myelodysplastic syndrome results of a phase II study
L Mannone, C Gardin, M C Quarre, et al.
Leukemia
|
February 2, 2013
Long-term outcome of anemic lower-risk myelodysplastic syndromes without 5q deletion refractory to or relapsing after erythropoiesis-stimulating agents
C Kelaidi, S Park, R Sapena, et al.
Leukemia
|
January 20, 2009
Is there a role for all-trans retinoic acid in combination with recombinant erythropoetin in myelodysplastic syndromes? A report on 59 cases
R Itzykson, S Ayari, D Vassilief, et al.
Leukemia Research
|
April 20, 2023
Effect of single-unit transfusion in patients treated for haematological disease including acute leukemia: A multicenter randomized controlled clinical trial
S P Chantepie, J B Mear, A R Briant, et al.
Annals of Hematology
|
January 30, 2013
High response rate and improved exercise capacity and quality of life with a new regimen of darbepoetin alfa with or without filgrastim in lower-risk myelodysplastic syndromes: a phase II study by the GFM
C Kelaidi, O Beyne-Rauzy, T Braun, et al.
Leukemia
|
October 27, 2015
Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion
A Toma, O Kosmider, S Chevret, et al.
Page
of 2